OMEGA PATENTS, LLC v. CALAMP CORP.
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Before Prost, Dyk, and Wallach. Appeal from the United States District Court for the Middle District of Florida.
Summary: Asserting the district court’s claim construction prevented consideration of additional prior art, without identifying the specific prior art, fails to meet the requirements of FRCP 46.
Omega sued CalAmp for patent infringement. The jury found willful infringement and found all asserted claims were not invalid. The district court awarded treble damages, attorney’s fees, damages for post-verdict sales, and pre-judgment interest. CalAmp appealed.
CalAmp argued the district court’s claim construction effectively prevented CalAmp from relying upon additional prior art to support its invalidity defense. The Federal Circuit rejected that argument because CalAmp failed to identify the art that may be impacted by the claim construction ruling. CalAmp failed to satisfy FRCP 46 by failing to seek admission into evidence of, or specifically identify, the additional prior art. Thus, the Federal Circuit affirmed on validity. However, the Federal Circuit found only a subset of accused products infringed a subset of the claims. The Federal Circuit vacated the willfulness finding because the jury verdict did not specify which claims CalAmp willfully infringed, and vacated the enhanced damages and attorney’s fees awards because they were based on the willfulness finding. The Federal Circuit also held that the district court abused its discretion in excluding CalAmp testimony regarding its mental state for willfulness. While such testimony could confuse the jury to believe it was relevant for determining infringement and validity, it was important for determining willfulness.
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…